Peer-influenced content. Sources you trust. No registration required. This is HCN.
Epoch Health
Viatris recalled one lot of Xanax XR 3-mg extended-release tablets after failed dissolution testing, with the FDA classifying the action as Class II and reporting no adverse events to date.
Family Medicine/General Practice April 29th 2026
Optometric Management
A nationwide recall of more than 3 million OTC eye drops due to sterility concerns highlights the importance of routine patient counseling around non‑prescription ocular products.
Ophthalmology April 20th 2026
The FDA notice added that a letter was sent out about the recall. However, it did not include a press release or other specific details.
Emergency Medicine March 26th 2026
Oncology News Central (ONC)
“Emerging data from this confirmatory study have highlighted a safety profile that is unfavorable compared to that previously observed in clinical evaluation.” — Christelle Huguet, PhD, Ipsen
Hematology/Oncology March 17th 2026
“Use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.” — FDA Class II Recall Definition
Cardiology March 10th 2026
Use of the affected products may lead to inconsistent therapeutic effects and an increase in potential gastrointestinal side effects in some patients.
Cardiology February 10th 2026
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS